Literature DB >> 19479395

[Therapy of asthma: anti-inflammatory effects of antileukotrienes].

D Ukena1.   

Abstract

The antileukotrienes (anti-LT), consisting of synthesis inhibitors and leukotriene receptor antagonists, represent a new direction in targeted drug therapy for asthma. In the present article, the anti-inflammatory properties of anti-LT are briefly summarized. Orally administered anti-LT inhibit the allergen-induced early and late asthmatic reactions and may attenuate the allergen-associated hyperresponsiveness. They also have a remarkable inhaled steroid-sparing effect. In chronic asthma, anti-LT may exert significant therapeutic benefit. In addition to their properties as relievers, anti-LT may have properties as controllers of asthma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 19479395     DOI: 10.1007/BF03041978

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  14 in total

1.  Inhaled corticosteroids: benefits and risks.

Authors:  D M Geddes
Journal:  Thorax       Date:  1992-06       Impact factor: 9.139

2.  Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma.

Authors:  S R Findlay; J M Barden; C B Easley; M Glass
Journal:  J Allergy Clin Immunol       Date:  1992-05       Impact factor: 10.793

3.  Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects.

Authors:  I K Taylor; K M O'Shaughnessy; R W Fuller; C T Dollery
Journal:  Lancet       Date:  1991-03-23       Impact factor: 79.321

4.  Use of inhaled corticosteroids and the risk of cataracts.

Authors:  R G Cumming; P Mitchell; S R Leeder
Journal:  N Engl J Med       Date:  1997-07-03       Impact factor: 91.245

5.  Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group.

Authors:  J Tamaoki; M Kondo; N Sakai; J Nakata; H Takemura; A Nagai; T Takizawa; K Konno
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

6.  A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings.

Authors:  G C Kane; M Pollice; C J Kim; J Cohn; R T Dworski; J J Murray; J R Sheller; J E Fish; S P Peters
Journal:  J Allergy Clin Immunol       Date:  1996-02       Impact factor: 10.793

Review 7.  [Theophylline: new information about a proven drug. The dual effect in therapy of bronchial asthma].

Authors:  D Ukena; A Keller; G W Sybrecht
Journal:  Med Klin (Munich)       Date:  1994-12-15

8.  Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.

Authors:  D J Evans; P J Barnes; S M Spaethe; E L van Alstyne; M I Mitchell; B J O'Connor
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

9.  Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.

Authors:  S E Wenzel; J B Trudeau; D A Kaminsky; J Cohn; R J Martin; J Y Westcott
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

10.  Comparison of patients' compliance with prescribed oral and inhaled asthma medications.

Authors:  J S Kelloway; R A Wyatt; S A Adlis
Journal:  Arch Intern Med       Date:  1994-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.